{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:04:58Z","timestamp":1784275498243,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06224-y","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:24:45Z","timestamp":1782804285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["International travel considerations for patients with systemic autoimmune inflammatory diseases in the era of novel immunosuppressive therapies"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-4023","authenticated-orcid":false,"given":"Robert J.","family":"Rolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9256-8052","authenticated-orcid":false,"given":"Simon M.","family":"Helfgott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-2234","authenticated-orcid":false,"given":"Camille N.","family":"Kotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"4","key":"6224_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5152\/eurjrheum.2020.19190","volume":"7","author":"F Szabados","year":"2020","unstructured":"Szabados F, Kragh J, Rasmussen C, Leutscher PDC (2020) Biological therapy and international travel: a questionnaire survey among Danish patients with rheumatic disease. Eur J Rheumatol 7(4):158\u201363. https:\/\/doi.org\/10.5152\/eurjrheum.2020.19190","journal-title":"Eur J Rheumatol"},{"issue":"10","key":"6224_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jama.2023.28019","volume":"331","author":"ML Martinson","year":"2024","unstructured":"Martinson ML, Lapham J (2024) Prevalence of immunosuppression among US adults. JAMA 331(10):880\u2013882. https:\/\/doi.org\/10.1001\/jama.2023.28019","journal-title":"JAMA"},{"issue":"3","key":"6224_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamainternmed.2022.6299","volume":"183","author":"J Wang","year":"2023","unstructured":"Wang J, Lee CC, Kesselheim AS, Rome BN (2023) Estimated medicaid spending on original and citrate-free adalimumab from 2014 through 2021. JAMA Intern Med 183(3):275\u2013276. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6299","journal-title":"JAMA Intern Med"},{"key":"6224_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw016","author":"JE Allen","year":"2016","unstructured":"Allen JE, Patel D (2016) Enquiries to the United Kingdom national travel advice line by healthcare professionals regarding immunocompromised travellers. J Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taw016","journal-title":"J Travel Med"},{"key":"6224_CR5","volume-title":"CDC yellow book 2026: health information for international travel","author":"Centers for Disease Control and Prevention (CDC)","year":"2025","unstructured":"Centers for Disease Control and Prevention (CDC) (2025) CDC yellow book 2026: health information for international travel. Oxford University Press"},{"issue":"3","key":"6224_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2022","unstructured":"Bass AR, Chakravarty E, Akl EA et al (2022) 2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken) 75(3):449\u2013464. https:\/\/doi.org\/10.1002\/acr.25045","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"6224_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6224_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jaad.2023.12.070","volume":"90","author":"VS Chat","year":"2024","unstructured":"Chat VS, Ellebrecht CT, Kingston P et al (2024) Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the national psoriasis foundation. J Am Acad Dermatol 90(6):1170\u20131181. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.070","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"6224_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/RHU.0000000000000624","volume":"24","author":"CV Brenol","year":"2018","unstructured":"Brenol CV, Azevedo VF, Bonvehi PE et al (2018) Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol 24(3):138\u2013147. https:\/\/doi.org\/10.1097\/RHU.0000000000000624","journal-title":"J Clin Rheumatol"},{"key":"6224_CR10","unstructured":"10. Vaccine Scheduler. European centre for disease prevention and control. Accessed 13 May 2026, https:\/\/vaccine-schedule.ecdc.europa.eu"},{"key":"6224_CR11","unstructured":"11. National Immunisation Program Scheduler. Australian government department of health disability and ageing. Accessed 13 May 2026, https:\/\/www.health.gov.au\/sites\/default\/files\/2026-01\/national-immunisation-program-schedule.pdf"},{"key":"6224_CR12","unstructured":"12. NHS vaccinations and when to have them. United Kingdom national health service. Accessed 13 May 2026, https:\/\/www.nhs.uk\/vaccinations\/nhs-vaccinations-and-when-to-have-them\/"},{"key":"6224_CR13","unstructured":"13. Vaccination Schedules Map. Pan American health organization. Accessed 13 May 2026, https:\/\/www.paho.org\/en\/get-up-to-date"},{"key":"6224_CR14","unstructured":"14. Immunization Data. World health organization. Accessed 13 May 2026, https:\/\/immunizationdata.who.int\/global?topic=&location="},{"issue":"2","key":"6224_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.15585\/mmwr.mm7402a3","volume":"74","author":"AP Wodi","year":"2025","unstructured":"Wodi AP, Issa AN, Moser CA, Cineas S (2025) Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older - United States, 2025. MMWR Morb Mortal Wkly Rep 74(2):30\u201333. https:\/\/doi.org\/10.15585\/mmwr.mm7402a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6224_CR16","unstructured":"16. OepnEvidence. AI-based medical information platform. OpenEvidence Inc.; 2023. Accessed 13 May 2026. https:\/\/www.openevidence.com\/."},{"key":"6224_CR17","unstructured":"17. Travelers\u2019 Health- Destinations. US centers for disease control and prevention. Accessed 8 September 2025, https:\/\/wwwnc.cdc.gov\/travel\/destinations\/list"},{"key":"6224_CR18","unstructured":"18. Foreign travel advice. Gov.UK. Accessed 12 May 2026, https:\/\/www.gov.uk\/foreign-travel-advice"},{"key":"6224_CR19","unstructured":"19. Staples JE, O\u2019Laughlin K. (2025) Yellow fever. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/yellow-fever.html."},{"key":"6224_CR20","unstructured":"20. Kotton CN, Kroger AT, Freedman DO. (2025) Immunocompromised travelers. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travelers-with-additional-considerations\/immunocompromised-travelers.html."},{"issue":"3","key":"6224_CR21","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2013","unstructured":"Rubin LG, Levin MJ, Ljungman P et al (2013) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58(3):e44-100. https:\/\/doi.org\/10.1093\/cid\/cit684","journal-title":"Clin Infect Dis"},{"key":"6224_CR22","unstructured":"22. COVID-19 Vaccination guidance for people who are immunocompromised. US centers for disease control and prevention. Accessed 8 September 2025, https:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies"},{"issue":"2","key":"6224_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4269\/ajtmh.12-0551","volume":"88","author":"M Jensenius","year":"2013","unstructured":"Jensenius M, Han PV, Schlagenhauf P et al (2013) Acute and potentially life-threatening tropical diseases in western travelers\u2013a GeoSentinel multicenter study, 1996\u20132011. Am J Trop Med Hyg 88(2):397\u2013404. https:\/\/doi.org\/10.4269\/ajtmh.12-0551","journal-title":"Am J Trop Med Hyg"},{"key":"6224_CR24","unstructured":"24. Ridpath AD, Wallender E. (2025) Malaria. In CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/malaria.html."},{"key":"6224_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133210","author":"W Zhang","year":"2019","unstructured":"Zhang W, Egashira N, Masuda S (2019) Recent topics on the mechanisms of immunosuppressive therapy-related neurotoxicities. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20133210","journal-title":"Int J Mol Sci"},{"key":"6224_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-16928-2_29","volume-title":"Neurorheumatology","author":"N Beckwith","year":"2019","unstructured":"Beckwith N, Helfgott S (2019) Neurologic and psychiatric effects of cytokines and targeted biological therapies. In: Cho T, Bhattacharyya S, Helfgott S (eds) Neurorheumatology. Springer, Cham. https:\/\/doi.org\/10.1007\/978-3-030-16928-2_29"},{"key":"6224_CR27","unstructured":"27. Connor BA, Leung DT. (2025) Travelers\u2019 diarrhea. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/preparing-international-travelers\/travelers-diarrhea.html."},{"key":"6224_CR28","unstructured":"28. Hackett PH, Schlim DR. (2025) High-altitude travel and altitude illness. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/environmental-hazards-risks\/high-altitude-travel-and-altitude-illness.html."},{"issue":"2","key":"6224_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ddg.14377","volume":"19","author":"B Stephan","year":"2021","unstructured":"Stephan B, Tittelbach J, Buhler S (2021) Considerations for patients with psoriasis travelling under immunosuppression. JDDG 19(2):197\u2013207. https:\/\/doi.org\/10.1111\/ddg.14377","journal-title":"JDDG"},{"issue":"11","key":"6224_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy266","volume":"5","author":"N Sbaih","year":"2018","unstructured":"Sbaih N, Buss B, Goyal D et al (2018) Potentially serious drug interactions resulting from the pretravel health encounter. Open Forum Infect Dis 5(11):ofy266. https:\/\/doi.org\/10.1093\/ofid\/ofy266","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"6224_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7207a1","volume":"72","author":"AB Brown","year":"2023","unstructured":"Brown AB, Miller C, Hamer DH et al (2023) Travel-related diagnoses among U.S. nonmigrant travelers or migrants presenting to U.S. GeoSentinel sites - GeoSentinel network, 2012\u20132021. MMWR Surveill Summ 72(7):1\u201322. https:\/\/doi.org\/10.15585\/mmwr.ss7207a1","journal-title":"MMWR Surveill Summ"},{"key":"6224_CR32","unstructured":"32. Chard AN, Hill V. (2025) Food and water precautions for travelers. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/preparing-international-travelers\/food-and-water-precautions-for-travelers.html."},{"key":"6224_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101700","volume":"37","author":"M Heinemann","year":"2020","unstructured":"Heinemann M, Omansen TF, Hennigs A et al (2020) Relapsing cutaneous leishmaniasis in a patient requiring TNF-\u03b1-inhibitor Infliximab for Takayasu-arteritis: case report and review of the literature. Travel Med Infect Dis 37:101700. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101700","journal-title":"Travel Med Infect Dis"},{"key":"6224_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40794-019-0092-x","volume":"5","author":"T Schwartz","year":"2019","unstructured":"Schwartz T, Jensenius M, Blomberg B, Fladeby C, Maeland A, Pettersen FO (2019) Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients. Trop Dis Travel Med Vaccines 5:16. https:\/\/doi.org\/10.1186\/s40794-019-0092-x","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"6224_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2023.102570","volume":"53","author":"H Hammarstrom","year":"2023","unstructured":"Hammarstrom H, Moreno J, Dotevall L, Calander AM (2023) Leishmania infantum infection after visiting southern Spain in patients on biological treatment; an observational, longitudinal, cohort study. Travel Med Infect Dis 53:102570. https:\/\/doi.org\/10.1016\/j.tmaid.2023.102570","journal-title":"Travel Med Infect Dis"},{"key":"6224_CR36","unstructured":"36. Find the Repellent that is Right for You. US environmental protection agency. https:\/\/www.epa.gov\/insect-repellents\/find-repellent-right-you"},{"key":"6224_CR37","unstructured":"37. Connelly CR, Gimnig JE. (2025) Mosquitoes, ticks, and other arthropods. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/environmental-hazards-risks\/mosquitoes-ticks-and-other-arthropods.html."},{"key":"6224_CR38","unstructured":"38. Atherstone CJ, Stoddard RA. (2025) Leptospirosis. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/leptospirosis.html. Accessed 7 August 2025,"},{"key":"6224_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.tmaid.2017.03.010","volume":"16","author":"ND Gundacker","year":"2017","unstructured":"Gundacker ND, Rolfe RJ, Rodriguez JM (2017) Infections associated with adventure travel: a systematic review. Travel Med Infect Dis 16:3\u201310. https:\/\/doi.org\/10.1016\/j.tmaid.2017.03.010","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"6224_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102655","volume":"18","author":"J Zhou","year":"2025","unstructured":"Zhou J, Jia Q, Liu L et al (2025) Epidemiology and clinical outcomes in skin and soft tissue nontuberculous mycobacteria infections: a retrospective study. J Infect Public Health 18(3):102655. https:\/\/doi.org\/10.1016\/j.jiph.2025.102655","journal-title":"J Infect Public Health"},{"key":"6224_CR41","unstructured":"41. Clinical Overview of Tuberculosis Disease. US centers for disease control and prevention. https:\/\/www.cdc.gov\/tb\/hcp\/clinical-overview\/tuberculosis-disease.html"},{"key":"6224_CR42","unstructured":"42. TB Incidence. World health organization. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024\/tb-disease-burden\/1-1-tb-incidence"},{"key":"6224_CR43","unstructured":"43. Jereb JA. (2025) Tuberculosis. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/tuberculosis.html."},{"issue":"14","key":"6224_CR44","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1177\/0961203319888688","volume":"28","author":"DS Oliveira","year":"2019","unstructured":"Oliveira DS, Hillal JPD, Cordova DDP, de Araujo DB (2019) The lupus patient traveller: a guide to the rheumatologist. Lupus 28(14):1690\u20131698. https:\/\/doi.org\/10.1177\/0961203319888688","journal-title":"Lupus"},{"key":"6224_CR45","unstructured":"45. Reyes NL, Abe K. (2025) Deep vein thrombosis and pulmonary embolism. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-air-sea\/deep-vein-thrombosis-and-pulmonary-embolism.html. Accessed 13 May 2026,"},{"key":"6224_CR46","unstructured":"46. Ridpath AD, Wallender E. (2025) Malaria. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/malaria.html. Accessed 30 October 2025,"},{"key":"6224_CR47","unstructured":"47. Vimkunya. US food and drug administration. Accessed 30 October 2025, https:\/\/www.fda.gov\/vaccines-blood-biologics\/vimkunya"},{"key":"6224_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taae125","author":"JL Schnyder","year":"2025","unstructured":"Schnyder JL, Garcia Garrido HM, Tanck MW et al (2025) Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-centre cohort study. J Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taae125","journal-title":"J Travel Med"},{"key":"6224_CR49","unstructured":"49. Hills SL, Lindsey NP. (2025) Japanese encephalitis. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/japanese-encephalitis.html. Accessed 30 October 2025,"},{"key":"6224_CR50","unstructured":"50. McNamara LA, Rubis AB. (2025) Meningococcal disease. In: CDC yellow book 2026: health information for international travel. Retrieved from URL. https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/meningococcal-disease.html. Accessed 30 October 2025,"},{"issue":"4","key":"6224_CR51","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/09733698241272078","volume":"19","author":"V Jain","year":"2024","unstructured":"Jain V, Mohanasundaram K, Kumar S et al (2024) Expert panel consensus statements on vaccination for adults with AIRD in India. Indian J Rheumatol 19(4):280\u2013295. https:\/\/doi.org\/10.1177\/09733698241272078","journal-title":"Indian J Rheumatol"},{"issue":"1","key":"6224_CR52","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14760584.2024.2401839","volume":"23","author":"M Rivera-Izquierdo","year":"2024","unstructured":"Rivera-Izquierdo M, Morales-Portillo A, Guerrero-Fernandez de Alba I et al (2024) Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024. Expert Rev Vaccines 23(1):887\u2013910. https:\/\/doi.org\/10.1080\/14760584.2024.2401839","journal-title":"Expert Rev Vaccines"},{"key":"6224_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay018","author":"V Hall","year":"2018","unstructured":"Hall V, Johnson D, Torresi J (2018) Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J Travel Med. https:\/\/doi.org\/10.1093\/jtm\/tay018","journal-title":"J Travel Med"},{"key":"6224_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00035-19","author":"JS Davis","year":"2020","unstructured":"Davis JS, Ferreira D, Paige E, Gedye C, Boyle M (2020) Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/CMR.00035-19","journal-title":"Clin Microbiol Rev"},{"key":"6224_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8010015","author":"A Ibrahim","year":"2018","unstructured":"Ibrahim A, Ahmed M, Conway R, Carey JJ (2018) Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8010015","journal-title":"J Clin Med"},{"issue":"Suppl 2","key":"6224_CR56","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Mariette X, Silva JT et al (2018) ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21\u2013S40. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.002","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"6224_CR57","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","volume":"24","author":"M Reinwald","year":"2018","unstructured":"Reinwald M, Silva JT, Mueller NJ et al (2018) ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect 24(Suppl 2):S53\u2013S70. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.009","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"6224_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM et al (2024) Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med 209(2):137\u2013152. https:\/\/doi.org\/10.1164\/rccm.202306-1113ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"6224_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/hematology.2020000116","volume":"2020","author":"L Malpica","year":"2020","unstructured":"Malpica L, Moll S (2020) Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program 2020(1):319\u2013327. https:\/\/doi.org\/10.1182\/hematology.2020000116","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"6224_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.autrev.2008.05.001","volume":"8","author":"R Caporali","year":"2008","unstructured":"Caporali R, Caprioli M, Bobbio-Pallavicini F, Montecucco C (2008) DMARDS and infections in rheumatoid arthritis. Autoimmun Rev 8(2):139\u201343. https:\/\/doi.org\/10.1016\/j.autrev.2008.05.001","journal-title":"Autoimmun Rev"},{"issue":"6","key":"6224_CR61","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s0049-0172(95)80009-3","volume":"24","author":"AM Boerbooms","year":"1995","unstructured":"Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB (1995) Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24(6):411\u201321. https:\/\/doi.org\/10.1016\/s0049-0172(95)80009-3","journal-title":"Semin Arthritis Rheum"},{"key":"6224_CR62","unstructured":"62. Anifrolumab (anifrolumab-fnia) injection, for intravenous use. US food and drug administration. Accessed 13 May 2026, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761123s000lbl.pdf"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06224-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:17:08Z","timestamp":1784272628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06224-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6224"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06224-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Robert J. Rolfe has received consultant honoraria from Bavarian Nordic and Oxon Medical. Camille N. Kotton has received consulting fees from Biotest, Kamada, ExeVir, Evrys, Hookipa, Takeda, Merck, Qiagen, Roche Diagnostics, Abbot Laboratories, honoraria from Takeda, Roche Diagnostics, Qiagen, Biotest, and has participated on a data safety monitoring board or advisory board for Takeda, Roche, Roche Diagnostics, Abbott Laboratories, Biotest, ExeVir, Kamada, Evrys. She has a leadership role in the Transplantation Society and a prior role on the US CDC Advisory Committee on Immunization Practice. Simon M. Helfgott has no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"173"}}